Clinical trial
Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies…
NCT00210951 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00210951 |
|---|---|
| Title | Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin |
| Official title | An Active Safety Surveillance Plan to Conduct Serologic Testing for Anti-erythropoietin Antibodies and Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa or Another Erythropoietin |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Red-Cell Aplasia, Pure, Chronic Renal Failure |
| Intervention type | Other |
| Interventions | No Intervention |
| Enrollment | 4,761 |
| Start date | May 1, 2003 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 24, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: